Several interpretation of improtant clinical trials on antihypertensive therapy / 中国实用内科杂志

ABSTRACT

In the PROFESS and TRANSCEND trials,telmisartan(80 mg daily),compared with placebo,reduced systolic blood pressure by about 4 mmHg,but did not influence the primary composite cardiovascular endpoint.The difference between the ACCOMPLISH and ALLHAT trials in the amlodipine-diuretic comparison might be attributed to the combination of amlodipine with an angiotensin converting enzyme inhibitor in the ACCOMPLISH trial,which provided further evidence that by smoothly controlling blood pressure over 24 hours amlodipine prevent vascular events better than other antihypertensive drugs.